Astal Laboratories Ltd

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a significant shift in its valuation parameters, moving from a previously very expensive rating to a very attractive valuation grade. This change comes amid a backdrop of mixed returns and sector challenges, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a notable upgrade in its quality grading from average to good, reflecting improvements in key business fundamentals. Despite this positive shift, the company’s stock performance remains under pressure, with a 4.58% decline on 3 June 2026 and a year-to-date return lagging behind the Sensex. This article analyses the underlying financial metrics driving the quality upgrade and assesses the implications for investors.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has reported a flat financial performance for the quarter ended March 2026, signalling a notable shift from its previously positive growth trajectory. Despite a robust surge in net sales, the company’s profitability metrics have deteriorated sharply, prompting a downgrade in its Mojo Grade from Strong Sell to Sell as of 16 February 2026.

Astal Laboratories Ltd., a micro-cap pharmaceutical intermediates and bulk drugs manufacturer, delivered a stunning 156.60% quarter-on-quarter revenue surge in Q4 FY26, yet the stock tumbled 3.24% to ₹71.46 on June 01, 2026, as investors grappled with sharply compressed margins and deteriorating profitability metrics. With a market capitalisation of ₹328.00 crores, the company's explosive topline expansion has failed to translate into bottom-line strength, raising critical questions about operational efficiency and sustainable growth.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This article analyses the recent changes in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, compares them with historical averages and peer companies, and assesses the implications for investors amid a challenging market backdrop.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has witnessed a significant shift in its valuation parameters, moving from an expensive to a very expensive rating. This change comes amid a strong day gain of 17.61% and a mixed performance relative to the Sensex over various time frames, prompting a detailed analysis of its price attractiveness and comparative metrics.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

For the third consecutive session, Astal Laboratories Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 61 on 27 Apr 2026. This marks a significant 40.8% drop from its 52-week high of Rs 103.2, underscoring persistent selling pressure despite some positive financial indicators.

For the second consecutive session, Astal Laboratories Ltd has closed lower, slipping to a fresh 52-week low of Rs 62.49 on 24 Apr 2026, extending its year-long decline despite some encouraging financial metrics.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astal Laboratories Ltd’s stock price declined to a fresh 52-week low of Rs.63 on 21 April 2026, marking a significant downturn amid a broadly rising market. The stock underperformed its sector and broader indices despite positive momentum in the Sensex, reflecting company-specific pressures and valuation concerns.

Astal Laboratories Ltd, a micro-cap player in the Trading & Distributors sector, has seen its valuation parameters shift notably, moving from a very expensive to an expensive rating. This change reflects a subtle but significant deterioration in price attractiveness, driven by a combination of elevated price-to-earnings and price-to-book ratios relative to historical and peer benchmarks. Investors face a challenging landscape as the stock underperforms broader indices and peers, prompting a reassessment of its investment appeal.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date perspective on its performance and outlook.

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.